Union Bancaire Privee UBP SA Has $674,000 Position in Moderna, Inc. (NASDAQ:MRNA)

Union Bancaire Privee UBP SA lowered its holdings in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 42.1% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 22,015 shares of the company's stock after selling 15,979 shares during the quarter. Union Bancaire Privee UBP SA's holdings in Moderna were worth $674,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of the business. FMR LLC raised its position in Moderna by 7.4% in the 4th quarter. FMR LLC now owns 18,664,634 shares of the company's stock valued at $776,075,000 after buying an additional 1,282,469 shares during the last quarter. Theleme Partners LLP raised its position in Moderna by 1.0% in the 4th quarter. Theleme Partners LLP now owns 7,306,861 shares of the company's stock valued at $303,819,000 after buying an additional 72,028 shares during the last quarter. Geode Capital Management LLC raised its position in Moderna by 2.4% in the 4th quarter. Geode Capital Management LLC now owns 7,241,354 shares of the company's stock valued at $300,219,000 after buying an additional 171,774 shares during the last quarter. Invesco Ltd. raised its position in Moderna by 24.3% in the 4th quarter. Invesco Ltd. now owns 5,006,462 shares of the company's stock valued at $208,169,000 after buying an additional 979,858 shares during the last quarter. Finally, Norges Bank acquired a new stake in Moderna in the 4th quarter valued at approximately $163,833,000. Institutional investors and hedge funds own 75.33% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the company. UBS Group dropped their target price on Moderna from $78.00 to $70.00 and set a "buy" rating on the stock in a research report on Friday, May 2nd. Royal Bank of Canada dropped their target price on Moderna from $32.00 to $28.00 and set a "sector perform" rating on the stock in a research report on Friday, May 2nd. Evercore ISI dropped their target price on Moderna from $50.00 to $32.00 and set an "in-line" rating on the stock in a research report on Friday, May 2nd. Citigroup assumed coverage on Moderna in a research report on Thursday, March 13th. They issued a "neutral" rating and a $40.00 target price on the stock. Finally, JPMorgan Chase & Co. decreased their price target on Moderna from $33.00 to $26.00 and set an "underweight" rating for the company in a research note on Thursday, May 22nd. Four analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average target price of $46.61.

Moderna Stock Down 2.5%

Shares of NASDAQ MRNA traded down $0.68 during midday trading on Friday, hitting $26.67. 7,146,605 shares of the company's stock were exchanged, compared to its average volume of 8,407,852. Moderna, Inc. has a 12 month low of $23.15 and a 12 month high of $139.92. The company's 50 day moving average price is $26.29 and its 200 day moving average price is $33.06. The firm has a market capitalization of $10.31 billion, a PE ratio of -2.87 and a beta of 1.86.

Moderna (NASDAQ:MRNA - Get Free Report) last issued its earnings results on Thursday, May 1st. The company reported ($2.52) EPS for the quarter, topping the consensus estimate of ($2.92) by $0.40. Moderna had a negative return on equity of 28.74% and a negative net margin of 110.04%. The company had revenue of $108.00 million during the quarter, compared to the consensus estimate of $130.35 million. During the same period in the previous year, the company posted ($3.07) EPS. The firm's revenue for the quarter was down 35.3% compared to the same quarter last year. On average, equities research analysts anticipate that Moderna, Inc. will post -9.61 EPS for the current year.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.